1. Home
  2. MRVI vs NPCT Comparison

MRVI vs NPCT Comparison

Compare MRVI & NPCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MRVI
  • NPCT
  • Stock Information
  • Founded
  • MRVI 2014
  • NPCT 2020
  • Country
  • MRVI United States
  • NPCT United States
  • Employees
  • MRVI 560
  • NPCT N/A
  • Industry
  • MRVI Biotechnology: Pharmaceutical Preparations
  • NPCT Investment Managers
  • Sector
  • MRVI Health Care
  • NPCT Finance
  • Exchange
  • MRVI Nasdaq
  • NPCT Nasdaq
  • Market Cap
  • MRVI 350.1M
  • NPCT 314.6M
  • IPO Year
  • MRVI 2020
  • NPCT N/A
  • Fundamental
  • Price
  • MRVI $2.42
  • NPCT $10.91
  • Analyst Decision
  • MRVI Hold
  • NPCT
  • Analyst Count
  • MRVI 10
  • NPCT 0
  • Target Price
  • MRVI $5.84
  • NPCT N/A
  • AVG Volume (30 Days)
  • MRVI 1.5M
  • NPCT 107.1K
  • Earning Date
  • MRVI 08-11-2025
  • NPCT 01-01-0001
  • Dividend Yield
  • MRVI N/A
  • NPCT 9.82%
  • EPS Growth
  • MRVI N/A
  • NPCT N/A
  • EPS
  • MRVI N/A
  • NPCT N/A
  • Revenue
  • MRVI $219,830,000.00
  • NPCT N/A
  • Revenue This Year
  • MRVI N/A
  • NPCT N/A
  • Revenue Next Year
  • MRVI $7.23
  • NPCT N/A
  • P/E Ratio
  • MRVI N/A
  • NPCT N/A
  • Revenue Growth
  • MRVI N/A
  • NPCT N/A
  • 52 Week Low
  • MRVI $1.67
  • NPCT $8.58
  • 52 Week High
  • MRVI $9.60
  • NPCT $10.63
  • Technical
  • Relative Strength Index (RSI)
  • MRVI 49.60
  • NPCT 48.99
  • Support Level
  • MRVI $2.28
  • NPCT $10.82
  • Resistance Level
  • MRVI $2.47
  • NPCT $10.98
  • Average True Range (ATR)
  • MRVI 0.14
  • NPCT 0.12
  • MACD
  • MRVI -0.01
  • NPCT -0.01
  • Stochastic Oscillator
  • MRVI 27.45
  • NPCT 48.15

About MRVI Maravai LifeSciences Holdings Inc.

Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.

About NPCT Nuveen Core Plus Impact Fund of Beneficial Interest

Nuveen Core Plus Impact Fund is an organized, diversified, closed-end management investment company. The Fund's investment objective is to seek total return through high current income and capital appreciation, while giving special consideration to certain impact and environmental, social and governance criteria.

Share on Social Networks: